Efinaconazole
Generic Name: efinaconazole
Brand Names:
Jublia
11 DESCRIPTION JUBLIA (efinaconazole) topical solution, 10% is a clear, colorless to pale yellow solution for topical use. Each gram of JUBLIA contains 100 mg of efinaconazole. Efinaconazole is an azole antifungal with a chemical name of ((2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol).
Overview
11 DESCRIPTION JUBLIA (efinaconazole) topical solution, 10% is a clear, colorless to pale yellow solution for topical use. Each gram of JUBLIA contains 100 mg of efinaconazole. Efinaconazole is an azole antifungal with a chemical name of ((2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol).
Uses
1 INDICATIONS AND USAGE JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . JUBLIA is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . (1)
Dosage
2 DOSAGE AND ADMINISTRATION Apply JUBLIA to affected toenails once daily for 48 weeks, using the integrated flow-through brush applicator. When applying JUBLIA, ensure the toenail, the toenail folds, toenail bed, hyponychium, and the undersurface of the toenail plate, are completely covered. JUBLIA is for topical use only and not for oral, ophthalmic, or intravaginal use. • Apply JUBLIA to affected toenails once daily for 48 weeks using the integrated flow-through brush applicator. (2) • When applying JUBLIA, ensure the toenail, the toenail folds, toenail bed, hyponychium, and the undersurface of the toenail plate, are completely covered. (2) • For topical use only. Not for oral, ophthalmic, or intravaginal use. (2)
Side Effects
6 ADVERSE REACTIONS The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two clinical trials, 1227 subjects were treated with JUBLIA, 1161 for at least 24 weeks and 780 for 48 weeks.
Interactions
7 DRUG INTERACTIONS In vitro studies have shown that JUBLIA, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.
Warnings
4 CONTRAINDICATIONS None. None. (4)
Pregnancy
8.1 Pregnancy Risk Summary There are no available human data for the use of JUBLIA during pregnancy to inform any drug associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, efinaconazole did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at subcutaneous doses up to 112 and 154 times, respectively, the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons.
Storage
Storage and Handling Conditions: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. • Solution is flammable; keep away from heat or flame. • Protect from freezing. • Keep out of reach of children. • Keep bottle tightly closed. • Store in upright position.
Frequently Asked Questions
What is Efinaconazole used for?▼
1 INDICATIONS AND USAGE JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . JUBLIA is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . (1)
What are the side effects of Efinaconazole?▼
6 ADVERSE REACTIONS The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two clinical trials, 1227 subjects were treated with JUBLIA, 1161 for at least 24 weeks and 780 for 48 weeks.
Can I take Efinaconazole during pregnancy?▼
8.1 Pregnancy Risk Summary There are no available human data for the use of JUBLIA during pregnancy to inform any drug associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, efinaconazole did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at subcutaneous doses up to 112 and 154 times, respectively, the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons.
What are the important warnings for Efinaconazole?▼
4 CONTRAINDICATIONS None. None. (4)
Related Medications
Purified Water, Glycerin, Propylene Glycol, Laurocapram, Niacinamide, Xanthan Gum, Butylene Glycol, Tocopherol, Cetearyl Alcohol, Isohexadecane, Ethylhexyl Palmitate, Caprylic/capric Triglyceride, Hydrogenated Lecithin, Cetearyl Glucoside, Polyacrylamide, C13-14 Isoparaffin, 1,2-hexanediol, Disodium Edta, Ergothioneine, Selaginella Tamariscina Extract, Ethylhexylglycerin, Glucose, Fragrance, Ginkgo Biloba Leaf Extract, Prunella Vulgairs Extract, Croton Lechleri Resin Extract
purified water, glycerin, propylene glycol, laurocapram, niacinamide, xanthan gum, butylene glycol, tocopherol, cetearyl alcohol, isohexadecane, ethylhexyl palmitate, caprylic/capric triglyceride, hydrogenated lecithin, cetearyl glucoside, polyacrylamide, c13-14 isoparaffin, 1,2-hexanediol, disodium edta, ergothioneine, selaginella tamariscina extract, ethylhexylglycerin, glucose, fragrance, ginkgo biloba leaf extract, prunella vulgairs extract, croton lechleri resin extract
Temporarily protects and helps relieve minor skin irritations Helps protect chapped or cracked skin
Hydrangea Arborescens Root, Saw Palmetto, Corn Silk, Elymus Repens Root, Agathosma Crenulata Leaf, Sodium Phosphate, Dibasic, Heptahydrate, And Dibasic Potassium Phosphate
hydrangea arborescens root, saw palmetto, corn silk, elymus repens root, agathosma crenulata leaf, sodium phosphate, dibasic, heptahydrate, and dibasic potassium phosphate
Water retention, edema.
Budesonide Inhalation
budesonide inhalation
Corticosteroid [EPC]
11 DESCRIPTION Budesonide, the active component of budesonide inhalation suspension, is a corticosteroid designated chemically as ( RS )-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20 dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two epimers (22R and 22S). The empirical formula of budesonide is C 25 H 34 O 6 and its molecular weight is 430.5.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.